Systemic Treatments for Metastatic Prostate Cancer in 2024.

IF 4.8 2区医学 Q1 UROLOGY & NEPHROLOGY

European urology focus Pub Date : 2024-08-09 DOI:10.1016/j.euf.2024.07.013

Marco Gizzi, Emmanuel Seront, Bertrand Tombal, Julien Van Damme

引用次数: 0

Abstract

Advanced metastatic prostate cancer is a heterogeneous disease for which androgen deprivation therapy combined with and androgen receptor pathway inhibitor (ARPI) is the mainstay of treatment. All available therapies may be used in sequence after the ARPI. However, patient selection is key. There is a need to identify clinical or molecular predictive factors to assist in selecting systemic treatment sequences.

查看原文本刊更多论文

2024 年转移性前列腺癌的系统治疗。

晚期转移性前列腺癌是一种异质性疾病，雄激素剥夺疗法联合雄激素受体通路抑制剂（ARPI）是其主要治疗手段。在使用 ARPI 后，可依次使用所有可用的疗法。然而，患者的选择是关键。有必要确定临床或分子预测因素，以帮助选择系统治疗顺序。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology focus Medicine-Urology

CiteScore

10.40

自引率

3.70%

发文量

274

审稿时长

23 days

期刊介绍： European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU). EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.